Akums Drugs and Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr
Revenue+5.9%
EBITDA+12.4%
Net Income−25.4%
EPS (adj.)−24.6%
Total Assets+32.4%
Total Equity+8.7%
Free Cash Flow+393.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AKUMS₹741.05

Akums Drugs and Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAGARWALEYEADVENZYMESAPLLTDAARTIPHARMAARTIDRUGSCORONAHCGMcap ₹11,346 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
Revenue+5.9
EBITDA+12.4
Net Income-25.4
EPS (adj.)-24.6
Total Assets+32.4
Total Equity+8.7
Free Cash Flow+393.4
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.